News
IMRX
1.640
+5.13%
0.080
Weekly Report: what happened at IMRX last week (0429-0503)?
Weekly Report · 31m ago
Buy Rating Affirmed: Immuneering’s Lead Asset IMM-1-104 Shows Promise Despite Market Skepticism
TipRanks · 4d ago
Weekly Report: what happened at IMRX last week (0422-0426)?
Weekly Report · 04/29 10:04
Weekly Report: what happened at IMRX last week (0415-0419)?
Weekly Report · 04/22 10:00
Weekly Report: what happened at IMRX last week (0408-0412)?
Weekly Report · 04/15 09:56
Immuneering Price Target Maintained With a $15.00/Share by Needham
Dow Jones · 04/12 10:42
Needham Reiterates Buy on Immuneering, Maintains $15 Price Target
Benzinga · 04/12 10:33
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Enlivex (ENLV), MacroGenics (MGNX) and Immuneering (IMRX)
TipRanks · 04/12 10:30
Buy Rating Affirmed for Immuneering Based on Promising IMM-1-104 Preclinical Data and Potential Enhanced Patient Outcomes in Pancreatic Cancer Treatment
TipRanks · 04/12 05:46
Immuneering Presented Preclinical Data At AACR annual Meeting For Ongoing Phase 2a Clinical Trial Of IMM-1-104 In RAS-Mutated Advanced Or Metastatic Solid Tumors
IMM-1-104 in combination with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibition than either treatment alone. Immuneering expects initial data from multiple Phase 2a arms of the study in 2024.
Benzinga · 04/09 16:04
IMMUNEERING CORP - EXPECTS INITIAL DATA FROM MULTIPLE IMM-1-104 PHASE 2A ARMS IN 2024
Reuters · 04/09 16:02
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
Barchart · 04/09 11:00
Weekly Report: what happened at IMRX last week (0401-0405)?
Weekly Report · 04/08 09:59
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Immuneering Corporation is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients. Management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024.
Barchart · 04/03 15:05
Immuneering Price Target Cut to $8.00/Share From $20.00 by Mizuho
Dow Jones · 04/02 12:01
Immuneering Is Maintained at Buy by Mizuho
Dow Jones · 04/02 12:01
IMMUNEERING CORP <IMRX.O>: MIZUHO CUTS TARGET PRICE TO $8 FROM $20
Reuters · 04/02 10:39
Weekly Report: what happened at IMRX last week (0325-0329)?
Weekly Report · 04/01 09:58
Buy Rating Affirmed for Immuneering on Solid Trial Progress and Insider Confidence
TipRanks · 03/29 08:26
Weekly Report: what happened at IMRX last week (0318-0322)?
Weekly Report · 03/25 10:00
More
Webull provides a variety of real-time IMRX stock news. You can receive the latest news about Immuneering Corp through multiple platforms. This information may help you make smarter investment decisions.
About IMRX
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the MAPK pathway. The Company’s second product candidate, IMM-6-415, aims to achieve universal-MAPK activity with an accelerated twice-daily oral dosing cadence, also through deep cyclic inhibition of the MAPK pathway. IMM-6-415 is in Investigational New Drug application (IND), enabling studies. Its pipeline also includes Trifecta MEK, RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.